Portal de Periódicos da CAPES

Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?

2009; Elsevier BV; Volume: 338; Issue: 5 Linguagem: Inglês

10.1097/maj.0b013e3181ae9227

1538-2990

Mark R. Goldblatt, John T. Huggins, Peter Doelken, Puncho Gurung, Steven A. Sahn,

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Dasatanib, which has been approved for rescue therapy for patients with imatinib-resistant chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, is a novel, orally available multitargeted kinase inhibitor of BCR-ABL and SRC family kinases (Quintas-Cardama et al, J Clin Oncol 2007;25:3908–14). It binds to both active and inactive conformations of the ABL gene and is 325 times more potent than imatinib in inhibiting the growth of BCR/ABL cells in vitro (Morelock and Sahn, Chest 1999;116:212–21; Huggins and Sahn, Clin Chest Med 2004;25:141–53). Although dasatinib is a generally well-tolerated drug in the treatment of Philadelphia chromosome positive hematopoetic malignancies, pleural effusions have been frequently noted and have been reported in up to 35% of patients (Sahn SA. Drug-induced pleural disease. In: Camus P, Rosenow E, editors. Drug-induced iatrogenic lung disease. London: Hodder Arnold; 2009). Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with dasatinib-induced pleural effusion with complete pleural fluid analysis.